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Abstract
AIM
To develop a MRI-based method for accurate deter-
mination of liver volume (LV) and to explore the effect 
of long-term everolimus (EVR) treatment on LV in PCK 
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rats with hepatomegaly. 
METHODS
Thirty-one female PCK rats (model for polycystic-liver-
disease: PCLD) were randomized into 3 groups and 
treatment was started at 16 wk, at the moment of 
extensive hepatomegaly (comparable to what is done 
in the human disease). Animals received: controls (n  
= 14), lanreotide (LAN: 3 mg/kg per 2 wk) (n  = 10) 
or everolimus (EVR: 1 mg/kg per day) (n  = 7). LV 
was measured at week 16, 24, 28. At week 28, all rats 
were sacrificed and liver tissue was harvested. Fibrosis 
was evaluated using quantitative image analysis. In 
addition, gene (quantitative RT-PCR) and protein 
expression (by Western blot) of the PI3K/AkT/mTOR 
signaling pathway was investigated. 
RESULTS
LV determination by MRI correlated excellent with 
the ex vivo  measurements (r  = 0.99, P  < 0.001). 
The relative changes in LV at the end of treatment 
were: (controls) +31.8%; (LAN) +5.1% and (EVR) 
+8.8%, indicating a significantly halt of LV progression 
compared with controls (respectively, P  = 0.01 and P  
= 0.04). Furthermore, EVR significantly reduced the 
amount of liver fibrosis (P  = 0.004) thus might also 
prevent the development of portal hypertension. There 
was no difference in phosphorylation of Akt (Threonine 
308) between LAN-treated PCK rats control PCK rats, 
whereas S6  was significantly more phosphorylated in 
the LAN group. Phosphorylation of Akt was not different 
between controls and EVR treated rats, however, for S6  
there was significantly less phosphorylation in the EVR 
treated rats. Thus, both drugs interact with the PI3K/
AkT/mTOR signaling cascade but acting at different 
molecular levels.
CONCLUSION
Everolimus halts cyst growth comparable to lanreotide 
and reduces the development of fibrosis. mTOR-
inhibition should be further explored in PCLD patients 
especially those that need immunosuppression.
Key words: Fibrocystic liver disease; mTOR inhibitor; 
Somatostatin analogue; Liver volume measurement; 
Magnetic resonance imaging
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: The continuous increase of liver cysts volume 
in polycystic-liver-disease (PCLD) leads to extensive 
hepatomegaly and portal hypertension, an indication for 
liver transplantation. The effect of mTOR-inhibition on 
liver volume (LV) in PCLD is unclear. We developed an 
accurate, non-invasive, MRI-based method to determine 
LV in a PCLD rat model. When treatment is started at 
the moment of extensive hepatomegaly (as in humans), 
the mTOR inhibitor everolimus halt disease progression 
and also of the development of fibrosis in this model. 
We speculate that everolimus, given after kidney 
transplantation in patients with PCLD, can prevent the 
development of symptomatic hepatomegaly. 
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INTRODUCTION
Polycystic liver disease (PCLD) is a fibrocystic liver 
diseases, a group of genetic disorders in which cysts 
occur either only in the liver, like in autosomal dominant 
PCLD, or in liver and the kidneys as in autosomal 
dominant polycystic kidney disease (ADPKD)[1,2]. 
In these patients due to the continuous increase in 
volume and number of cysts, the liver enlarges and 
may become disabling and in advanced stages, the 
patients develop portal hypertension[3]. 
The rat Pck gene is orthologous to the human 
PKHD1 gene and responsible for Autosomal Recessive 
Polycystic Kidney Disease. The animals have a splicing 
mutation in the Pkhd1 gene encoding fibrocystin/
polyductin (FPC). FPC and polycystin-1 and -2, -proteins 
mutated in human ADPKD-, are co-localized to the 
primary cilium of the cholangiocytes. The PCK rat is 
used worldwide as model to study PCLD[4-7]. 
Two key signaling pathways have been implicated 
in the increased proliferation of PCK cholangiocytes 
leading to cyst formation. First, the defective ciliary 
structure in the cholangiocytes and integrated sensory/
transducing functions result in a decreased intracellular 
Ca2+ and increased cytosolic cyclic adenosine mono-
phosphate [cAMP]cyt, causing cholangiocyte proliferation, 
abnormal cell-matrix interactions, and altered fluid 
secretion. Basal levels of cAMP are maintained by the 
orchestration of multiple factors in which somatostatin 
receptors (SSTRs) play an important role. Octreotide, 
a somatostatin analogue, with high binding affinity for 
SSTR2 and 5, decreases [cAMP]cyt and reduces liver-
cyst volume in the PCK rat. Both lanreotide (LAN) and 
octreotide reduce liver volume (LV) in patients with 
PCLD[8-13]. 
The other important pathway involves the 
mammalian target of Rapamycin (mTOR). mTOR 
is a serine/threonine kinase present in two distinct 
complexes. The first is mTOR complex 1 (mTORC1), 
composed of mTOR, Rptor (Raptor: Regulatory 
Associated Protein of mTOR, Complex 1), GβL, and 
DEPTOR. It is a master growth-regulator that senses 
and integrates diverse nutritional and environmental 
factors. The second complex, mTOR complex 2 
(mTORC2), is composed of mTOR, Rictor, GβL, Sin1, 
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PRR5/Protor-1, and DEPTOR. mTORC2 promotes 
cellular survival by activating Akt, regulates cytoskeletal 
dynamics and controls ion transport and growth[14,15]. 
Increased activation of the Phosphatidylinositol-4,5-
bisphosphate 3-kinase/AkT/ mTOR (PI3K/Akt/mTOR) 
pathway has also been shown to be involved in the 
cystic proliferation of cholangiocytes of the PCK rat. 
Sirolimus, an mTOR inhibitor, delayed cyst growth 
in the Han:SPRD rat model and in a mouse model 
of ADPKD[16,17]. In human ADPKD patients, sirolimus 
reduced LV in patients who underwent kidney trans-
plantation in one study[18]. However, the evidence of a 
beneficial effect of mTOR inhibitors to reduce LV in the 
PCK rat and in prospective studies in humans is not 
robust[19,20]. 
From preclinical studies performed in the PCK rat 
and from human PCLD data, is it clear that the hepatic 
cystic disease progression shows large inter-individual 
variability. To overcome this we explored the value of 
non-invasive repeated measurements of LV by MRI in 
the PCK rat. 
The aims of the present study were therefor: (1) to 
develop an MRI-based method to evaluate accurately 
changes in LV in a rat model of PCLD; and (2) to 
investigate the long-term efficacy of everolimus (EVR) 
on liver disease when administered starting at the 
moment of already marked hepatomegaly, a situation 
mimicking the clinical situation. 
MATERIALS AND METHODS
Experimental protocol 
Thirty-one 10-wk-old female PCK rats (Charles River, 
France) were used for this study. This rat model is 
derived from a Crj:CD (Sprague Dawley) rat strain, 
originating in Japan[4-7]. The animals were housed in 
an environment with normal humidity and a 12/12 
daylight cycle receiving a normal diet. They were 
randomly assigned to three groups: (1) controls; (2) 
LAN as positive control; or (3) EVR. At week 16, when 
the animals had developed extensive hepatomegaly, 
baseline MRI was performed. The next day, therapy 
was started and continued for a period of 3 mo. No 
animals died or were excluded for other reasons over 
the entire study period. At indicated times (week 16, 
24 and 28), serial MRI were performed (Figure 1). 
All rats were sacrificed the day after their last MRI at 
week 28 using Nembutal anesthesia. After vertical 
laparotomy, the hepatic hilum and hepatic veins were 
clipped simultaneously to avoid change in LV by loss of 
blood. Livers were removed, weighted and the ex vivo 
LV was determined using a graduated glass cylinder 
filled with saline 0.9% at 37 ℃ (accuracy of 1 mL). 
Tissue samples were stored for molecular analysis in 
Trizol (Invitrogen/Life Technologies, United States), 
snap-frozen for protein analysis and fixed with formalin 
for histology. 
All animal experiments were approved by the 
Ethical Committee for animal welfare (KU Leuven, 
P164/2010).
Study drugs
Lanreotide 3 mg/kg was administered every 2 wk 
intramuscular (somatuline, gift from Ipsen Pharma; 
Merelbeke, Belgium). Everolimus oral solution 1 mg/kg 
per day (Certican®; gift from Novartis Pharma; Basel, 
Switzerland) was administered via the drinking water 
without further additives. Dosages were chosen based 
on previous published data[10,12,20]. We used black 
drinking bottles to ensure light protection in the EVR 
group. Drug solutions were freshly prepared every 
morning and adjusted to body weight and fluid intake 
once weekly.
Liver volumetry 
The PCK rats were anaesthetized with Isoflurane 
2% and placed in a human wrist coil. MRI scanning 
(1.5T MRI scanner; slice thickness 0.3 cm; inter-slice 
gap: 0.03 cm) for liver volumetry was performed by 
3 radiologists, blinded for the study groups; on the 
day before the start of treatment (week 16), at week 
24 and at week 28 (i.e., 8 and 12 wk after the start 
of therapies). T1 and T2 weighted MR images were 
acquired. Liver area was measured and summed for 
all slices of T2 weighted images by using a built-in 
freehand region of interest (Figure 2A). Then, the LV 
was calculated using the following formula: LV = Σ 
liver area on each slice × (slice thickness + gap).
Fibrosis
Liver samples were fixed in buffered formalin (4%), 
washed in PBS and embedded in paraffin. Picrosirius 
red collagen staining was performed to measure 
fibrosis. All liver biopsies were analyzed by an expert 
liver pathologist, blinded for the groups. Fibrosis 
was assessed using Olympus Stream image analysis 
software 1.9 Software following image acquisition 
using a light microscope and color digital camera 
(Olympus CMOS camera SC30 Münster, Germany). 
Fibrosis was scored by 2 independent researchers and 
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MRI                                   MRI                             MRI
Week 16                            Week 24             Week 28
Controls (n  = 14)
Lanreotide 3 mg/kg per 2 wk (n  = 10)
Everolimus 1 mg/kg per day (n  = 7)
Start of treatment                                      End of treatment
Figure 1  Study design. Female PCK rats were obtained at age week 10. At 
week 16, a first MRI was performed to calculate the liver volume. Animals were 
randomly assigned to one of the groups and treatment was started. At week 
24 and week 28 a new MRI was performed, after the last measurement the 
animals were sacrificed and tissue collected for protein and gene assay.
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P-Akt (Thr308,#) anti-Tot Akt (#2967), all purchased 
from Cell Signaling Technology (Beverly, Massachusetts, 
United States), and β-actin (Sigma-Aldrich, St. Louis, 
MO, United States) as loading control. Thereafter, the 
corresponding secondary horseradish peroxidase-
coupled antibodies were applied to the membranes 
for one hour (Dako, Heverlee, Belgium). After addition 
of enhanced chemiluminescence reagent (Pierce ECL 
Western Blotting Substrate, #32106, Thermo Scientific/
Life Technologies, Carlsbad, CA, United States), 
digital detection was performed using ChemiDoc™ 
imaging system with Image Lab™ image acquisition 
software (Biorad). Expression of P-S6Rp, total S6Rp, 
P-Akt, and total Akt was normalized to β-actin levels. 
For comparison of different blots, a pool of liver 
homogenates of 28-wk-old Sprague Dawley rat livers 
was placed on each gel as internal control.
Quantitative Real-Time polymerase chain reaction 
Gene expression was assessed by quantitative reverse 
transcriptase polymerase chain reaction (qRT-PCR). 
RNA was isolated from tissue stored in Trizol with the 
RNeasy Kit (Qiagen, Chatsworth, CA, United States) 
according to the manufacturer’s instructions. One 
microgram of cellular RNA was transcribed into cDNA 
using SuperScript II reverse transcriptase and random 
hexamer primers (Invitrogen/Life Technologies, United 
States). The PCR reaction was carried out in a mixture 
expressed as percentage of total liver parenchyma 
from 4 random selected samples per animal.
Western blotting
Liver samples stored at -80 ℃ were homogenized 
using Tissue Lyzer LT (Qiagen) in RIPA buffer at 4 ℃ (50 
mmol/L Tris pH 8.0, 150 mmol/L NaCl, 0.01% sodium 
dodecyl sulfate, 1% NP-40 (nonionic polyoxyethylene 
surfactant), 0.5% sodium desoxycholaat, 1 mmol/L 
1-phenylmethylsulfonyl fluoride) containing protease 
inhibitor mix (Complete Protease Inhibitor Cocktail, 
Roche Applied Science, Penzberg, Germany). Protein 
concentrations were assessed with the BCA-kit (Abcam, 
Cambridge United Kingdom) and the protein in the 
lysates were adjusted to the same concentration (40 
μg/20 μL). SDS sample buffer (62.5 mmol/L Tris, 
10% glycerol, 2% sodium dodecyl sulfate, 0.05% 
Bromophenol blue and β-mercaptoethanol) was 
added, samples were boiled for 5 min and separated 
on miniprotean TGX anykD gel from Biorad (Biorad, 
Hercules, CA, United States). After electrotransfer to 
nitrocellulose membrane and blocking in Phosphate-
buffered saline (PBS) containing 0.1% Tween and 
5% non-fat dried milk, the membranes were over-
night incubated with the primary antibody in PBS 
supplemented with 0.1% Tween and 5% non-fat 
dry milk powder. Antibodies used were: anti-P-S6Rp 
(Ser235/236, #4858), anti-Tot S6Rp (#2217), anti-
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Figure 2  Liver volume measurements. A: Demonstration of liver volume measured by MRI on each liver-containing slice of T2 weighted images. The liver margin 
is contoured manually with the red line; B: Correlation between liver volume calculated from MRI scan and liver volume measured ex vivo. Pearson correlation (r) 
is given together with significance; C: Liver volume (mean ± SE) determined by MRI for the different groups: CON (controls, n = 14), LAN (n = 10) and EVR (n = 7), 
measured at start of treatment, and after 8 and 12 wk. aP < 0.05 vs animals in control group at corresponding time, NS: Not significant, vs control. The percentual 
change in LV (ΔLV) over the 12 wk experimental period is shown together with the P value vs control group. LAN: Lanreotide; EVR: Everolimus.
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that contained appropriate sense- and anti-sense 
primers and a probe in Taqman Univeral PCR Master 
Mixture (Applied Biosystems, Foster City, United 
States) (Table 1). β-2 microglobulin (B2M) was used 
as house-keeping gene. Each sample was assayed in 
duplicate on an A7500 Fast Real-Time PCR System 
(Applied Biosystems). The mean ∆Ct value (with SE) 
vs the reference (B2M) was calculated. 
Statistical analysis
Data were analyzed using MedCalc version 14.12.0 
(Medcalc, Ostend, Belgium: http://www.medcalc.
org). Descriptive statistics including mean and SE for 
continuous variables were computed or median with 
IQR (interquartile range) (25%-75%) as appropriate. 
Differences in continuous variables between treated 
and non-treated rats were investigated using, One 
Way ANOVA, t-test for independent samples or the 
Mann Whitney U test, as appropriate. Repeated 
measurements ANOVA and serial measurements were 
used to compare paired observations between groups, 
as appropriate. To assess correlations, non-parametric 
testing Pearson correlation coefficient was determined. 
Bland-Altman plots assessed agreement in accuracy 
of the techniques. To compare percentages between 
groups, χ2 was used. All P values resulted from two-
sided statistical tests, and P < 0.05 is considered 
significant. 
RESULTS
Liver volume
To validate MRI as a tool, we determined LV by two 
methods. (1) In vivo LV was determined by MRI 
(Figure 2A); and (2) To measure the LV ex vivo, we 
removed the liver at the end of the experiment (week 
28, corresponding with 3 mo of treatment). Pearson 
correlation between in vivo LV (MRI) and ex vivo LV was 
excellent (r = 0.99, P < 0.001) (Figure 2B) and that 
allows us to use MRI as a reliable method to explore 
LV. At baseline rat body weight (gram) in the 3 groups: 
controls, LAN and EVR were not different, respectively: 
316 (SE: 3.2); 318 (SE: 5.6) and 299 (SE: 2.7). Also 
at baseline, the median LV’s (range) for controls, LAN 
and EVR, were not different, respectively: 19.6 mL 
(17.0; 21.7); 18.7 mL (17.0; 20.0); 19.4 mL (17.8; 
20.6) (P = 0.754). The mean of the relative increase in 
LV (95%CI) in the 3 groups after 12 wk of treatment 
(from week 16 to week 28) was respectively: +31.8% 
(19.0;44.0); +5.1% (-12.0; 23.0) and +8.8% (-1.7; 
19.0). Both treatment groups (LAN, EVR) significantly 
halted LV progression compared with controls (P = 0.01 
and P = 0.04). The absolute LVs at different times are 
given in Figure 2C. There was no significant difference 
in effect on LV between LAN and EVR after 8 wk or 12 
wk of treatment. 
Fibrosis 
Fibrosis, scored independently by 2 researchers, 
showed excellent agreement with a difference of 
0.5% (95%CI: -0.2-1.3). In the 14 control PCK rats 
[mean percentage fibrosis: 14.7% (SE: 1.8)], we 
found a strong Pearson correlation (r) between LV 
(MRI) and the relative amount of fibrosis (r = 0.93; P 
< 0.0001) (Figure 3A). EVR significantly suppressed 
the development of fibrosis in PCK rats (P = 0.004) 
whereas LAN showed a trend to reduction (P = 0.095) 
(Figure 3B). Representative histological images of 
picrosirius red staining are shown in Figure 3C. 
Protein expression
Expression of components of the PI3K/Akt/mTOR 
pathway was investigated. In the control animals, 
we observed a very strong correlation between the 
p-Akt/Akt phosphorylation ratio and the LV (r = 0.7, 
P < 0.003) while the p-S6/S6 ratio correlated only 
moderately (r = 0.47, P = 0.088) (Figure 4A).
There was no difference in phosphorylation of 
Akt (Threonine 308) between LAN-treated PCK rats 
control PCK rats, whereas S6 was significantly more 
phosphorylated in the LAN group. The p-S6/S6 ratios 
for LAN and controls were respectively: 2.01 (0.98; 
2.53) and 0.33 (0.16; 0.76) (P < 0.001). The level 
of phosphorylation of Akt at Threonine 308 was not 
different between controls and EVR treated rats. 
However, S6 was significantly less phosphorylated in 
the EVR treated rats (Figure 4C and D). 
These observations indicate that both drugs 
interact with the PI3K/AkT/mTOR signaling cascade 
but acting at different molecular levels (Figure 4B), 
both mechanisms leading to halting of the disease in 
this model of PCLD. 
Gene expression 
LAN and EVR treated rats showed a significant lower 
gene expression of SSTR2 while expression of SSTR5 
was increased (borderline significant) in the LAN 
treated rats (Figure 5). EVR treatment resulted in 
a decreased SSTR5 gene expression compared to 
LAN treated animals. After 12 wk of treatment, we 
observed an increased gene expression of mTOR but 
not of Rptor in the EVR treated rats vs controls. LAN 
treatment did not affect gene expression of mTOR. 
Demonstrating again that both drugs have different 
Table 1  Real-time polymerase chain reaction primer probes 
used in this study
Gene Full name Assay ID applied biosystems
SSTR2 somatostatin receptor 2 Rn01464950_g1
SSTR5 somatostatin receptor 5 Rn02535169_s1
mTOR mechanistic target of 
rapamycin (serine/threonine 
kinase)
Rn00693900_m1
Rptor regulatory associated protein 
of mTOR, complex 1
Rn01464431_m1
B2M beta-2 microglobulin Rn00560865_m1
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mechanisms of action on cyst growth.
DISCUSSION
Similar to what is observed in human PCLD patients; 
we found a large inter- and intra-litter variation of 
the severity of hepatic polycystic disease in the PCK 
model, which had previously also been found by 
Mason et al[21]. Therefore, there is a great need for 
a reliable technique that can accurately assess LV in 
this animal model and further that allows repeated 
measurements during drug treatment. High Resolution 
Ultrasonography has recently been used to assess 
renal cysts in the PCK rats[22]. Also, as an indirect 
assessment method, T1 relaxation time was proposed 
as an imaging marker of liver disease for the PCK 
model[23] but neither of these was used to determined 
LV. For the current study, we explored MRI T2 weighted 
images to longitudinally measure LV and to investigate 
individual responses. We validated this method in 
the PCK model. We showed that it is accurate and 
reproducible, with an excellent correlation between LV 
determined by MRI and ex vivo LV determination. The 
assessment with MRI allowed us to detect changes in 
the same animal in time accurately. Treatment with 
LAN was used as positive treatment control and as 
expected, we observed an increase in LV with placebo 
and a stabilization with LAN, an observation similar to 
what is seen in patients with PCLD[10-13]. 
Important to note is that no animals died or were 
excluded for other reasons over the entire study 
period. Using this non-invasive technique, we could 
drastically reduce the number of animals necessary for 
this study. 
In the present study, we investigated the effect of 
the mTOR inhibitor EVR on cyst growth since its effect 
in humans or in the corresponding animal model, is still 
unclear and controversial due to the limited number 
of available studies[20,24]. We found that EVR prevented 
cyst enlargement in the PCK rat model, using a clinical 
relevant experimental design in which we started the 
treatment at the moment of severe hepatomegaly, 
mimicking the clinical situation in humans. The study 
was restricted to female rats since symptomatic PCLD 
mainly affects mostly women and because it has been 
demonstrated that female PCK rats display a more 
progressive liver enlargement compared to male PCK 
rats. 
Treatment with LAN induced a reduction of SSTR2 
gene expression (in agreement with the expected 
molecular effect of LAN). In line with previous findings 
of Masyuk et al[8] with octreotide and pasireotide, 
we also observed upon treatment with LAN a mild 
reduction in fibrosis compared to untreated animals 
that might be an indirect effect of lower growth of 
the liver cysts. With EVR however, we observed a 
significant reduction of the amount of fibrosis, which 
may be explained by the well-known direct effect 
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Figure 3  Liver fibrosis in PCK rats and effect of treatment with lanreotide or everolimus. Picrosirius red collagen staining was performed on formalin fixed, 
paraffin embedded liver tissue, staining was assessed using Olympus Stream image analysis software 1.9 Software. Fibrosis was expressed as percentage of 
total liver parenchyma from 4 random selected samples per animal. A: Pearson correlation (r) and significance for liver volume with fibrosis in control animals; B: 
Amount of fibrosis relative to total parenchyma in the livers of PCK rats after 12 wk of treatment with LAN or EVR and in controls. Results are given as mean and 
SE; C: Representative images of the amount of fibrosis by picrosirius red staining in the 3 groups (original magnification × 40). CON: Control; LAN: Lanreotide; EVR: 
Everolimus.
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of mTOR inhibition on fibrosis progression[25]. Since 
PCLD, belonging to the fibrocystic liver diseases, is 
complicated in a later stage by portal hypertension, 
the present observations further support an additional 
potential clinical benefit of this drug on portal hyper-
tension by reducing the amount of fibrosis.
The molecular observations made in this model (the 
combination of protein and gene expression) indicate a 
dysregulation of the PI3K/AkT/mTOR signaling cascade 
by both LAN and EVR, each acting at a different level 
and both mechanisms leading to halting of the disease. 
mTOR is a serine/threonine kinase and can form two 
protein complexes: mTORC1 (mTOR, Rptor), which is 
inhibited EVR, and mTORC2 (mTOR, Rictor). Ribosomal 
protein S6 kinase (S6K) is the direct downstream 
target of mTORC1 and regulates the downstream 
translational initiation machinery to control cell growth, 
proliferation and autophagy. mTORC 2 controls 
actin cytoskeleton and resistance to apoptosis. In 
animals treated with EVR, we observed an increased 
mTOR gene expression which is probably due to the 
prolonged administration of EVR in an attempt of the 
cell to compensate for the inhibitory effects of EVR on 
mTOR. S6-protein, downstream of mTOR, was less 
phosphorylated in EVR-treated animals compared to 
control PCK rats. Renken and colleagues investigated 
sirolimus in PCK rats, the time-dependent effect 
was assessed by using different groups sacrificed at 
different time points. No longitudinal follow-up of LV 
in the same animal was performed their study. They 
could only observe subtle effects of sirolimus on mTOR-
specific S6 kinase in the liver[26]. The large inter- and 
intra-litter variability of hepatic disease progression 
may explain why they in their study could not observe 
a beneficial effect on liver disease progression. Further 
studies on the molecular mechanisms involved in PCLD 
in (pre)clinical models are needed.
In conclusion, our method of LV measurement with 
MRI is shown to be highly sensitive and allowed us to 
detect accurately changes in time in a non-invasive 
way. Long-term everolimus treatment halts liver cyst 
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growth and reduces the development of fibrosis in this 
rat model. Our observations support the rational to 
explore further everolimus for the prevention of the 
development of symptomatic liver disease, such as in 
patients with ADPKD after kidney transplantation who 
are in need of an immunosuppressive drug.
COMMENTS
Background
The polycystic liver diseases (PCLD) represent a group of genetic disorders, 
in which cysts occur in the liver (ADPLD), or occur as well in the liver as in the 
kidneys (ADPKD). In PCLD, the liver becomes polycystic at a late stage, e.g., 
in ADPKD patients, the prevalence is 85%, and 94% in subgroups of age (resp. 
25 to 34, and 35 to 46 year). Most of the patients with PCLD are asymptomatic; 
however, in a subpopulation of 1%-3%, expansion of liver cysts cause 
invalidating abdominal symptoms furthermore, symptomatic ADPLD patients 
are mainly females. The most common complication in patients with PCLD is 
extensive hepatomegaly, which may lead to malnutrition and can be lethal and 
cyst-related complications include hemorrhage, infections, and rupture. There 
is no medical treatment approved for PCLD and to date, the only definitive 
treatment in those patients with large liver volumes (LV) is liver transplantation 
(LT).
Research frontiers
Octreotides and lanreotides have been shown to reduce LV in patients with 
PCLD, beneficial effects of mTOR-inhibition in patients is still a matter of debate. 
This was investigated in these experiments in the PCK-rat model of PCLD as 
preclinical evaluation. The authors designed the study representative for the 
hospital situation and started treatment at the moment of marked hepatomegaly 
(representing the symptomatic female patient). They developed and validated a 
MRI-based method to determine LV that can be used for longitudinal follow-up 
of disease progression and supported the observations with molecular analysis. 
Innovations and breakthroughs
The authors developed a unique MRI-based method that was shown to be 
sensitive and statistically reliable. Repeat measurements allowed for monitoring 
individual responses and reducing the number of animals required for this type 
of study. This method is a great step forward for it allows preclinical testing 
of drugs for PCLD under controlled conditions. Everolimus looks beneficial to 
reduce the cyst volume in PCLD with a secondary benefit on fibrosis. 
Applications
The imaging technique that they describe can be used to study drugs or drug 
combinations in preclinical setting in the representative animal model of PCK 
rats that for logistic reasons (number of symptomatic patients, slow progress 
of the disease, inter-individual variation of progression) is difficult to organize 
in patients. Ultimately, this approach can lead to a reduction of patients that 
require a transplantation. Polycistic liver and kidney diseases are closely 
related. Kidney transplantation is a frequent treatment for autosomal dominant 
polycystic kidney disease (ADPKD, autosomal dominant PKD or adult-onset 
PKD), and this study gives arguments to use everolimus in patients that need 
immunosuppression as it can have beneficial effects for the livers at risk in 
ADPKD patients and complications due to progressive fibrosis. 
Peer-review
In this study, authors have shown that everolimus halts hepatic cystogenesis 
in a rodent model of PCLD. They have developed a MRI-based method for 
accurate determination of LV and investigated that everolimus halted cyst 
growth comparable to lanreotide and reduced the development of fibrosis, 
mTOR-inhibition should be further explored in PCLD patients especially those 
that need immunosuppression. The study has been well performed.
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